



PROTOCOL

AN OPEN-LABEL EXTENSION STUDY OF XEN496 IN PEDIATRIC SUBJECTS WITH *KCNQ2* DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY



Sponsor: Xenon Pharmaceuticals Inc.
200-3650 Gilmore Way
Burnaby, BC
V5G 4W8
Canada

Study Number: XPF-009-302

Clinical Study Identifier: EPIK OLE

IND Number: 138144 **EudraCT Number:** 2020-003447-28

Compound: Ezogabine (USAN)/Retigabine (INN)

Version: 3.0 **Date:** 09 May 2022

Previous Versions:

- 2.0, dated 04 Apr 2022
- 1.0, dated 29 Sept 2020

CONFIDENTIALITY STATEMENT

Information in this protocol is confidential and should not be disclosed, other than to those directly involved in the execution or the ethical/regulatory review of the study, without prior written authorization from Xenon Pharmaceuticals Inc. or its affiliates.

STATEMENT OF COMPLIANCE

The study will be carried out in accordance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use-Good Clinical Practice (ICH-GCP) and applicable regulatory requirements.


The protocol, informed consent form(s), recruitment materials, and all subject materials will be submitted to the ethics committee/institutional review board (EC/IRB) for review and approval. Approval of both the protocol and the consent form must be obtained before any subject is enrolled. Any amendment to the protocol will require review and approval by the EC/IRB. In addition, all changes to the consent form will be EC/IRB-approved; a determination will be made regarding whether a new consent needs to be obtained from subjects who provided consent, using a previously approved consent form.

SPONSOR APPROVAL

STUDY TITLE: An Open-label Extension Study of XEN496 in Pediatric Subjects With *KCNQ2* Developmental and Epileptic Encephalopathy

I, the undersigned, have read this protocol and agree that it contains all necessary information required to conduct the study.

SIGNATURES:



Signature Manifest

Revision: 01

Title: XPF-009-302 EPIK-OLE Protocol V3.0

Effective Date: 09 May 2022

All dates and times are in Pacific Time.

XPF-009-302 EPIK-OLE Protocol V3.0

Approval

Meaning/Reason

Approved

Approved

Approved

Approved

INVESTIGATOR AGREEMENT

STUDY TITLE: An Open-label Extension Study of XEN496 in Pediatric Subjects With *KCNQ2* Developmental and Epileptic Encephalopathy

By signing below, I agree that:

I have read this protocol. I approve this document and I agree that it contains all necessary details for carrying out the study as described. I will conduct this study in accordance with the design and specific provisions of this protocol and will make a reasonable effort to complete the study within the time designated. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] understand that the study may be terminated or enrollment suspended at any time by Xenon, with or without cause, or by me if it becomes necessary to protect the best interests of the study subjects.

I agree to conduct this study in full accordance with applicable local regulations, ethics committee/institutional review board regulations, and International Council for Harmonisation Guidelines for Good Clinical Practice.

Investigator's Signature

Date

Investigator's Printed Name

COORDINATING INVESTIGATOR AGREEMENT

STUDY TITLE: An Open-label Extension Study of XEN496 in Pediatric Subjects With *KCNQ2* Developmental and Epileptic Encephalopathy

By signing below, I agree that:

I have read this protocol. I approve this document and I agree that it contains all necessary details for carrying out the study as described. I will conduct this study in accordance with the design and specific provisions of this protocol and will make a reasonable effort to complete the study within the time designated. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] I understand that the study may be terminated or enrollment suspended at any time by Xenon, with or without cause, or by me if it becomes necessary to protect the best interests of the study subjects.

I agree to the assigned responsibility for the coordination of investigators at different centers participating in the multicenter trial.

I agree to conduct this study in full accordance with applicable local regulations, ethics committee/institutional review board regulations, and International Council for Harmonisation Guidelines for Good Clinical Practice.

Coordinating Investigator's Signature

Date

Coordinating Investigator's Printed Name

TABLE OF CONTENTS

STATEMENT OF COMPLIANCE.....	2
SPONSOR APPROVAL.....	3
INVESTIGATOR AGREEMENT.....	4
COORDINATING INVESTIGATOR AGREEMENT	5
TABLE OF CONTENTS	6
LIST OF IN-TEXT TABLES.....	10
LIST OF IN-TEXT FIGURES	10
1. PROTOCOL SUMMARY	11
1.1. Synopsis	11
1.2. Schema.....	18
1.3. Schedule of Activities.....	19
2. INTRODUCTION.....	27
2.1. Study Rationale	27
2.2. Background	28
2.3. Benefit/Risk Assessment	28
2.3.1. Known Potential Benefits	28
2.3.2. Known Potential Risks.....	29
2.3.3. Assessment of Potential Benefits and Risks	31
3. OBJECTIVES AND ENDPOINTS.....	33
4. STUDY DESIGN	35
4.1. Overall Design.....	35
4.1.1. Screening/Baseline Period	35
4.1.2. Treatment Period	35
4.1.3. Taper Period and End of Study	36
4.2. Scientific Rationale for Study Design	36
4.3. Justification for Dose.....	36
4.3.1. Background PK Data to Support Dose Justification	36
4.3.2. Dose Adjustments Due to Concomitant Medication Use	37
4.3.3. Treatment Duration.....	38
4.4. End of Study Definition.....	38
5. STUDY POPULATION	39

5.1.	Inclusion Criteria	39
5.2.	Exclusion Criteria	39
5.3.	Lifestyle Considerations	39
5.3.1.	Prohibited Medications and Substances	39
5.3.2.	Permitted Medications and Therapies	40
5.3.3.	Rescue Medication	40
5.4.	Criteria for Discontinuation or Withdrawal of a Subject.....	41
5.4.1.	Withdrawal from the Study	41
5.5.	Discontinuation/Withdrawal of Study Drug	41
5.6.	Lost to Follow-up	42
6.	STUDY DRUG	43
6.1.	Study Drug Administration.....	43
6.1.1.	Description of Study Drug/Matching Placebo	43
6.1.2.	Dosing and Administration	43
6.2.	Preparation/Handling/Storage/Accountability	45
6.2.1.	Acquisition and Accountability	45
6.2.2.	Study Drug Storage and Stability	46
6.2.3.	Study Drug Preparation	46
6.3.	Measures to Minimize Bias.....	46
7.	STUDY ASSESSMENTS AND PROCEDURES	47
7.1.	Efficacy Assessments	47
7.1.1.	Seizure Assessments	47
7.1.2.	Caregiver Diary	47
7.1.3.	Caregiver Global Impression of Severity and Change Scales	48
7.1.4.	Clinician Global Impression of Change Scale	48
7.1.5.	Quality of Life Scales	48
7.1.6.	Behavior and Development Assessments	49
7.1.7.	Sleep Quality	49
7.1.8.	Palatability Questionnaire	49
7.2.	Safety, PK, and Other Assessments.....	49
7.2.1.	Physical and Neurologic Examinations	50
7.2.2.	Vital Signs, Weight, and Height.....	50
7.2.3.	ECG Measurements	50

7.2.6.	Assessment of Suicidal Ideation.....51
7.2.7.	Clinical Laboratory Tests.....51
7.2.8.	PK and ASM Blood Samples.....52
7.2.9.	Estimated Blood Volume Collection.....53
7.2.10.	Study Drug Compliance.....55
7.3.	AEs and SAEs.....55
7.3.1.	Definition of AEs.....55
7.3.2.	Definition of SAEs.....56
7.3.3.	Classifications of an AE.....56
7.3.4.	Time Period and Frequency for Event Assessment and Follow-up.....57
7.3.5.	Reporting of Pregnancy.....61
8.	STATISTICAL CONSIDERATIONS.....62
8.1.	Sample Size Determination.....62
8.2.	Populations for Analyses.....62
8.2.1.	Safety Population.....62
8.2.2.	Key Efficacy Analysis Set.....62
8.2.3.	Secondary Efficacy Analysis Set.....62
8.3.	Statistical Analyses.....62
8.3.1.	General Approach.....62
8.3.2.	Analyses of Safety Endpoints.....62
8.3.3.	Analysis of the Key Efficacy Endpoint.....63
8.3.4.	Analysis of Additional Efficacy Endpoints.....64
8.3.5.	Handling of Missing Data.....64
8.3.6.	Planned Interim Analysis.....64
8.3.7.	Tabulation of Individual Participant Data.....64
8.3.8.	PK Analysis.....64
9.	SUPPORTING DOCUMENTATION.....65
9.1.	Regulatory, Ethical, and Study Oversight Considerations.....65
9.1.1.	Informed Consent Process.....65
9.1.2.	Study Termination and Closure.....65
9.1.3.	Confidentiality and Privacy.....66

9.1.5.	DSMB	67
9.1.6.	Clinical Monitoring	67
9.1.7.	Quality Assurance and Quality Control.....	67
9.1.8.	Data Handling and Record Keeping.....	68
9.1.9.	Protocol Deviations	69
9.1.10.	Publication and Data Sharing Policy	69
9.1.11.	Conflict of Interest Policy	69
9.2.	Additional Considerations.....	70
9.3.	List of Abbreviations	71
10.	REFERENCES.....	73
11.	APPENDICES.....	76
APPENDIX A.	SEIZURE DEFINITIONS.....	77
APPENDIX B.	CAREGIVER GLOBAL IMPRESSION OF SEVERITY SCALES	78
APPENDIX C.	CAREGIVER GLOBAL IMPRESSION OF CHANGE SCALES	79
APPENDIX D.	CLINICIAN GLOBAL IMPRESSION OF CHANGE SCALES	82
APPENDIX E.	SLEEP QUALITY QUESTIONS.....	83
APPENDIX F.	CAREGIVER IMPRESSION OF STUDY DRUG PALATABILITY	84
APPENDIX G.	LIST OF PROHIBITED CONCOMITANT MEDICATIONS.....	85

LIST OF IN-TEXT TABLES

Table 1	Schedule of Activities, Baseline and Treatment Period Up to 1 Year	19
Table 2	Schedule of Activities, Long-term Treatment Period (up to 3 Years), and Taper and Follow-up Visits.....	23
Table 3	Titration Scheme	44
Table 4	Clinical Laboratory Tests.....	51



LIST OF IN-TEXT FIGURES

Figure 1	Study Design Schematic	18
Figure 2	Pediatric Systemic Exposure Relative to Historical Adult Data	37

1. PROTOCOL SUMMARY

1.1. Synopsis

Protocol Title:	An Open-label Extension Study of XEN496 in Pediatric Subjects With <i>KCNQ2</i> Developmental and Epileptic Encephalopathy
Protocol Number:	XPF-009-302
Protocol Identifier:	EPIK OLE
Phase:	Phase 3
Study Drug:	<p>XEN496: Immediate-release, multi-particulate sprinkle capsule formulation of ezogabine (retigabine) for pediatric subjects.</p> <p>Placebo: Matching capsules containing inactive ingredients (used only during the double-blind transition/titration period).</p> <p>The capsules are meant to be opened and the contents dispersed into soft foods or liquids for oral administration [REDACTED]</p>
Indication:	Treatment of seizures in pediatric subjects with <i>KCNQ2</i> developmental and epileptic encephalopathy (KCNQ2-DEE).
Study Description:	An international, multicenter, open-label extension (OLE) study to assess the long-term safety, tolerability, and efficacy of XEN496 in pediatric subjects with KCNQ2-DEE who participated in the primary efficacy and safety study (XPF-009-301).
Objectives:	<p><u>Primary Objective:</u></p> <ul style="list-style-type: none"> To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2-DEE who had participated in the primary study (XPF-009-301). <p><u>Secondary Objectives:</u></p> <ul style="list-style-type: none"> To evaluate the intrasubject efficacy of XEN496 in reducing seizure frequency compared to prior placebo treatment in pediatric subjects with KCNQ2-DEE who were previously randomized to receive placebo in the primary double-blind Phase 3 study (XPF-009-301). To assess the long-term effect of XEN496 on seizure reduction in pediatric subjects treated with XEN496. To evaluate Caregiver Global Impression of Severity (CaGI-S) and Caregiver Global Impression of Change (CaGI-C) scores in pediatric subjects with KCNQ2-DEE. To assess neurocognitive development and behavior after dosing with XEN496 in pediatric subjects with KCNQ2-DEE. To evaluate the investigator's global impression of the change in the subject's overall condition, assessed using the Clinical Global Impression of Change (CGI-C) scale. To evaluate the use of rescue medication and change in background antiseizure medications (ASM).

	<ul style="list-style-type: none"> To assess the impact of XEN496 on the quality of life of caregivers and subjects with KCNQ2-DEE. To evaluate the plasma concentrations of ezogabine and <i>N</i>-acetyl metabolite of retigabine (ezogabine) (NAMR).
Study Population:	Approximately 40 pediatric subjects diagnosed with KCNQ2-DEE who participated in the primary study (XPF-009-301).
Study Duration:	<p>Subjects will undergo:</p> <ul style="list-style-type: none"> Screening/Baseline period – subjects will undergo eligibility assessment at Visit 22 or early termination in the primary study (XPF-009-301). Treatment period – 36 months: <ul style="list-style-type: none"> Blinded transition/titration period – 24 days. Open-label period – approximately 35 months. Taper period – Up to 15 days. <p>Subjects who discontinue or complete the study treatment will be required to taper off study drug over a period of up to 15 days.</p> <ul style="list-style-type: none"> Follow-up – Approximately 4 weeks after subjects have tapered off study drug. <p>Total study duration per subject is estimated to be 37 months.</p>
Study Design:	<p>Study Type: Interventional.</p> <p>Estimated Enrollment: Approximately 40 subjects.</p> <p>Intervention: Single group, open-label treatment with XEN496.</p> <p>Description: This is an open-label, long-term extension study of XEN496 for the treatment of seizures in subjects with KCNQ2-DEE, that will be open to eligible subjects who participated in the primary study, XPF-009-301. The primary objective is to assess the long-term safety of XEN496.</p> <p>The study includes a screening/baseline visit to assess eligibility. A double-blind transition/titration period will be used to maintain blinding to the treatment allocation in the primary study (XPF-009-301).</p> <p>After completion of the blinded transition/titration period, subjects will continue to receive the study drug at their optimal dose for approximately 35 months.</p> <p><u>Screening/Baseline:</u></p> <p>Screening/baseline procedures and assessments will be conducted at Visit 22 or early termination in the primary study (XPF-009-301); procedures and assessments in addition to those required at these visits may be conducted in order to confirm eligibility for the OLE study.</p> <p><u>Treatment Period:</u></p> <p><i>Blinded Transition/Titration Period:</i></p> <p>Subjects who received XEN496 in the primary study will continue to receive XEN496 at the same dose throughout the OLE.</p> <p>Subjects allocated to placebo in the primary study will be required to begin a titration of XEN496 [REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>The transition/titration will be performed in a blinded manner to maintain the blind to the treatment arm from the primary study.</p> <p><i>Open-label Period:</i></p> <p>Following the transition/titration period, subjects will continue open-label treatment at their optimal dose of XEN496 for approximately 35 months.</p> <p><u>Taper Period and End of Study:</u></p> <p>At the end of the treatment period, subjects will be required to taper off study drug over a period of up to 15 days.</p> <p>Subjects who discontinue the study early will be required to enter into the taper period at that time and will be expected to complete the end of study follow-up safety monitoring schedule.</p> <p>Subjects will be monitored for safety for 28 days after the last dose of study drug has been administered.</p>
<p>Criteria for Subject Selection:</p>	<p><u>Criteria for Inclusion:</u></p> <p>To be eligible to participate in the study, an individual must meet all of the following criteria:</p> <ol style="list-style-type: none"> 1. Subject completed participation as defined in the primary study, XPF-009-301. A subject who withdraws from the primary study due to meeting protocol-specified worsening criteria will be considered as having completed participation in the primary study. 2. The caregiver is willing and able to comply with diary completion, visit schedule, and study drug administration requirements. 3. Subject's caregiver achieved a minimum of 85% compliance with daily diary completion during both baseline and the double-blind period of the primary study. <p><u>Criteria for Exclusion:</u></p> <p>Any subject who meets any of the following criteria will not qualify for entry into the study:</p> <ol style="list-style-type: none"> 1. Any adverse event (AE) or serious adverse event (SAE) during Study XPF-009-301, which in the opinion of the investigator and sponsor's medical monitor, would preclude the subject's entry into the OLE. 2. A clinically significant condition or illness, or symptoms other than those resulting from KCNQ2-DEE, present at screening/baseline that, in the opinion of the investigator, would pose risk to the subject if s/he were to enter the study. 3. Any conditions that were specified as exclusion criteria in the primary study (XPF-009-301). 4. It is anticipated that the subject will require treatment with at least one of the disallowed medications during the study. 5. [REDACTED]

Treatment Allocation:	All subjects rolling over into the OLE study will receive active treatment with XEN496. Subjects will undergo a blinded transition/titration period, regardless of their treatment allocation in the primary study (XPF-009-301).																												
Dose Administration and Discontinuation:	<p><u>Dose Administration:</u></p> <p>XEN496 is supplied as sprinkle capsules at 3 dose strengths of [REDACTED] [REDACTED] Capsules in dose strengths of [REDACTED] will be dispensed when subjects complete their transition or titration period.</p> <p>The daily dose of XEN496 is calculated based on body weight and should be administered orally 3 times daily (TID) in equally divided doses (as supplied by the pharmacy). The entire contents of the capsules containing XEN496 [REDACTED] of a soft food or liquid prior to ingestion.</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><u>Treatment Period:</u></p> <p><i>Blinded Transition/Titration Period:</i></p> <p>The treatment period begins with a dose transition/titration period.</p> <p>Subjects who received XEN496 in the preceding study will continue to receive XEN496 at the same dose, in a blinded manner, without any further titration.</p> <p>Subjects allocated to placebo in the preceding study, [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>The following dose titration scheme is approximate. The final dose and number of capsules using the weight-based dosing are detailed in the pharmacy manual.</p> <table><tr><th>[REDACTED]</th><th>[REDACTED]</th><th>[REDACTED]</th><th>[REDACTED]</th></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr><tr><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td></tr></table> <p>[REDACTED]</p> <p>The investigator will be blinded during the transition/titration period. Assuming no moderate to severe treatment-related AEs occur, the subject’s dose will be escalated to the next dose level during titration according to the dosing regimen.</p> <p>The maximum dose will not exceed [REDACTED]</p> <p>[REDACTED]</p>	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]																										


	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><i>Open-label Period:</i></p> <p>The optimally-tolerated dose level established during the transition/titration period will be maintained throughout the duration of the open-label period unless dose adjustment is required.</p> <p>The investigator will assess the subject's tolerability and AE profile throughout the treatment period. [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p><u>Dose Taper Period:</u></p> <p>Subjects who complete the study or exit the study early should have the dose reduced in a stepwise manner [REDACTED] that were used during titration, but in reverse order.</p>
<p>Outcome Measures:</p>	<p><u>Safety Endpoints:</u></p> <ul style="list-style-type: none"> Severity and frequency of AEs and SAEs; clinically significant changes in laboratory tests, vital signs, electrocardiograms (ECGs), physical and neurologic examinations, [REDACTED] <p><u>Key Efficacy Endpoint:</u></p> <ul style="list-style-type: none"> Change in monthly countable motor seizure frequency, comparing the first 15 weeks of XEN496 treatment in the OLE study to the seizure frequency reported during treatment in the preceding primary study (XPF-009-301), among only those subjects who were randomized to the placebo arm in the primary study (XPF-009-301). <p><u>Additional Endpoints:</u></p> <ul style="list-style-type: none"> Change from pre-randomization baseline in the previous study over time based on response categories (<25%, 25 to <50%, 50 to <75%, 75 to <100%, 100%), based on estimated seizure frequency every 3 months during the OLE period. Percent change from baseline in countable motor seizure frequency, relative to pre-randomization baseline of the previous study (XPF-009-301), assessed over time every 3 months during the OLE. Percent change from baseline in countable motor seizure frequency, relative to pre-randomization baseline of the previous study (XPF-009-301), for every 3 months based on combined data from both XPF-009-301 and the OLE, by the treatment group in the previous study.

Statistical Considerations:

	<div></div> <div></div> <div></div> <div></div> <div></div>
Sample Size Determination:	Approximately 40 subjects may be included in the study based on the number of subjects who could roll over from Study XPF-009-301 .

1.2. Schema


Figure 1 Study Design Schematic




been treated for at least 15 weeks in the open-label extension.

1.3. Schedule of Activities


The Schedule of Activities is presented in 2 tables. [Table 1](#) includes the baseline and treatment period up to 1 year, and [Table 2](#) includes the long-term treatment period (up to 3 years), and taper and follow-up visits.

















STATISTICAL ANALYSIS PLAN

Available upon request.